Hikma Pharmaceuticals (HIK) Share Forecast & Price Target

Compare

87 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

HIK Analyst Ratings

Strong Buy

4 Buy

1 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Hikma

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

HIK Stock 12 Month Forecast

Average Price Target

2,266.00p

▲(49.47% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Hikma Pharmaceuticals in the last 3 months. The average price target is 2,266.00p with a high forecast of 2,400.00p and a low forecast of 2,100.00p. The average price target represents a 49.47% change from the last price of 1,516.00p.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1794":"1,794p","2401":"2,401p","1945.75":"1,945.8p","2097.5":"2,097.5p","2249.25":"2,249.3p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2400,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">2.40K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2266,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">2.27K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">2.10K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1794,1945.75,2097.5,2249.25,2401],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1839,1882.1538461538462,1925.3076923076924,1968.4615384615386,2011.6153846153845,2054.769230769231,2097.923076923077,2141.076923076923,2184.230769230769,2227.3846153846152,2270.5384615384614,2313.6923076923076,2356.846153846154,{"y":2400,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1839,1871.8461538461538,1904.6923076923076,1937.5384615384614,1970.3846153846155,2003.2307692307693,2036.076923076923,2068.923076923077,2101.769230769231,2134.6153846153848,2167.4615384615386,2200.3076923076924,2233.153846153846,{"y":2266,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1839,1859.076923076923,1879.1538461538462,1899.2307692307693,1919.3076923076924,1939.3846153846155,1959.4615384615386,1979.5384615384614,1999.6153846153845,2019.6923076923076,2039.7692307692307,2059.846153846154,2079.923076923077,{"y":2100,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1849.48,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1812.7,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1871.74,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1928.84,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2218.22,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2090.47,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1919.44,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1969.69,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2116.5,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1962.79,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1910.57,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1795,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1839,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target2,400p

Average Price Target2,266p

Lowest Price Target2,100p

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

James Vane

Jefferies

2,360p

Buy

55.67%

Upside

Reiterated

11/07/25

Hikma Pharmaceuticals (HIK) Receives a Buy from Jefferies

Unknown Analyst

Peel Hunt

Not Ranked

Peel Hunt

2,170p

Buy

43.14%

Upside

Reiterated

11/07/25

Peel Hunt Keeps Their Buy Rating on Hikma Pharmaceuticals (HIK)

Victoria Lambert

Berenberg Bank

2,510p→2,300p

Buy

51.72%

Upside

Reiterated

11/06/25

Hikma Pharmaceuticals (HIK) Receives a Buy from Berenberg Bank

Sidhartha Modi

Barclays

2,300p→2,100p

Hold

38.52%

Upside

Reiterated

11/06/25

Barclays Keeps Their Hold Rating on Hikma Pharmaceuticals (HIK)

Zain Ebrahim

J.P. Morgan

2,400p

Buy

58.31%

Upside

Reiterated

11/06/25

Hikma Pharmaceuticals (HIK) Gets a Buy from J.P. Morgan

Kane Slutzkin

Deutsche Bank

3,100p→2,850p

Buy

87.99%

Upside

Reiterated

08/13/25

Deutsche Bank Sticks to Its Buy Rating for Hikma Pharmaceuticals (HIK)

Alistair Campbell

RBC Capital

2,625p

Buy

73.15%

Upside

Reiterated

08/11/25

Hikma Pharmaceuticals (HIK) Gets a Buy from RBC Capital

Unknown Analyst

Bank of America Securities

Not Ranked

Bank of America Securities

2,380p

Hold

56.99%

Upside

Initiated

06/09/25

Hikma Pharmaceuticals (HIK) Initiated with a Hold at Bank of America Securities

Victor Floc'h

Exane BNP Paribas

2,650p

Buy

74.80%

Upside

Initiated

05/14/25

BNP Paribas Exane Starts Hikma Pharmaceuticals Plc (HIK:LN) (HKMPF) at OutperformBNP Paribas Exane analyst Victor Floch initiates coverage on Hikma Pharmaceuticals Plc (HIK:LN) (OTC: HKMPF) with a Outperform rating and a price target of GBP26.50.

Christian Glennie

Stifel Nicolaus

2,650p

Buy

74.80%

Upside

Reiterated

04/24/25

Promising Financial Outlook and Strategic Positioning of Hikma Pharmaceuticals: A Buy Recommendation by Christian Glennie

Thibault Boutherin

Morgan Stanley

2,100p→2,400p

Hold

58.31%

Upside

Reiterated

02/12/25

Hikma Pharmaceuticals Plc (HIK:LN) (HKMPF) PT Raised to GBP24 at Morgan StanleyMorgan Stanley analyst Thibault Boutherin raised the price target on Hikma Pharmaceuticals Plc (HIK:LN) (OTC: HKMPF) to GBP24.00 (from GBP21.00) while maintaining a Equalweight rating.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

James Vane

Jefferies

2,360p

Buy

55.67%

Upside

Reiterated

11/07/25

Hikma Pharmaceuticals (HIK) Receives a Buy from Jefferies

Unknown Analyst

Peel Hunt

Not Ranked

Peel Hunt

2,170p

Buy

43.14%

Upside

Reiterated

11/07/25

Peel Hunt Keeps Their Buy Rating on Hikma Pharmaceuticals (HIK)

Victoria Lambert

Berenberg Bank

2,510p→2,300p

Buy

51.72%

Upside

Reiterated

11/06/25

Hikma Pharmaceuticals (HIK) Receives a Buy from Berenberg Bank

Sidhartha Modi

Barclays

2,300p→2,100p

Hold

38.52%

Upside

Reiterated

11/06/25

Barclays Keeps Their Hold Rating on Hikma Pharmaceuticals (HIK)

Zain Ebrahim

J.P. Morgan

2,400p

Buy

58.31%

Upside

Reiterated

11/06/25

Hikma Pharmaceuticals (HIK) Gets a Buy from J.P. Morgan

Kane Slutzkin

Deutsche Bank

3,100p→2,850p

Buy

87.99%

Upside

Reiterated

08/13/25

Deutsche Bank Sticks to Its Buy Rating for Hikma Pharmaceuticals (HIK)

Alistair Campbell

RBC Capital

2,625p

Buy

73.15%

Upside

Reiterated

08/11/25

Hikma Pharmaceuticals (HIK) Gets a Buy from RBC Capital

Unknown Analyst

Bank of America Securities

Not Ranked

Bank of America Securities

2,380p

Hold

56.99%

Upside

Initiated

06/09/25

Hikma Pharmaceuticals (HIK) Initiated with a Hold at Bank of America Securities

Victor Floc'h

Exane BNP Paribas

2,650p

Buy

74.80%

Upside

Initiated

05/14/25

Christian Glennie

Stifel Nicolaus

2,650p

Buy

74.80%

Upside

Reiterated

04/24/25

Promising Financial Outlook and Strategic Positioning of Hikma Pharmaceuticals: A Buy Recommendation by Christian Glennie

Thibault Boutherin

Morgan Stanley

2,100p→2,400p

Hold

58.31%

Upside

Reiterated

02/12/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Hikma Pharmaceuticals

1 Month

xxx

Success Rate

10/14 ratings generated profit

Average Return

+3.53%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 71.43% of your transactions generating a profit, with an average return of +3.53% per trade.

3 Months

xxx

Success Rate

3/7 ratings generated profit

Average Return

+2.77%

reiterated a xxx

rating 8 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 42.86% of your transactions generating a profit, with an average return of +2.77% per trade.

1 Year

James VaneJefferies

Success Rate

4/14 ratings generated profit

Average Return

-7.72%

reiterated a buy rating last month

Copying James Vane's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -7.72% per trade.

2 Years

xxx

Success Rate

4/14 ratings generated profit

Average Return

-4.60%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 28.57% of your transactions generating a profit, with an average return of -4.60% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HIK Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, HIK has received 13 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. HIK average Analyst price target in the past 3 months is 2,266.00.

Each month's total comprises the sum of three months' worth of ratings.

HIK Financial Forecast

HIK Earnings Forecast

Next quarter’s earnings estimate for HIK is 0.81p with a range of 0.81p to 0.81p. The previous quarter’s EPS was 0.92p. HIK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year HIK has Performed in-line its overall industry.

HIK Sales Forecast

Next quarter’s sales forecast for HIK is 1.26B with a range of 1.26B to 1.27B. The previous quarter’s sales results were 1.28B. HIK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year HIK has Performed in-line its overall industry.

HIK Stock Forecast FAQ

What is GB:HIK’s average 12-month price target, according to analysts?

Based on analyst ratings, Hikma Pharmaceuticals PLC’s 12-month average price target is 2,266.00.

What is GB:HIK’s upside potential, based on the analysts’ average price target?

Hikma Pharmaceuticals PLC has 49.47% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Hikma Pharmaceuticals PLC a Buy, Sell or Hold?

Hikma Pharmaceuticals PLC has a consensus rating of Strong Buy, which is based on 4 buy ratings, 1 hold ratings and 0 sell ratings.

What is Hikma Pharmaceuticals PLC’s share price target?

The average share price target for Hikma Pharmaceuticals PLC is 2,266.00. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is 2,400.00p ,and the lowest forecast is 2,100.00p. The average share price target represents 49.47% Increase from the current price of 1,516p.

What do analysts say about Hikma Pharmaceuticals PLC?

Hikma Pharmaceuticals PLC’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of Hikma Pharmaceuticals PLC?

To buy shares of GB:HIK, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Hikma Pharmaceuticals (HIK) Share Forecast & Price Target

HIK Analyst Ratings

HIK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Hikma Pharmaceuticals

HIK Analyst Recommendation Trends

HIK Financial Forecast

HIK Earnings Forecast

HIK Sales Forecast

HIK Stock Forecast FAQ

Detailed List of Analyst Forecasts